

Supporting Information

Optimization of the Lactam Side Chain of 7-Azaindenoisoquinoline

Topoisomerase I Inhibitors and Mechanism of Action Studies in Cancer Cells

Evgeny Kiselev,^{1,‡} Dhriti Sooryakumar,^{2,‡} Keli Agama,² Mark Cushman,^{*,1} and Yves Pommier^{*,2}

Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, and The Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana, 47907; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-4255

*To whom correspondence should be addressed. Mark Cushman: Phone: 765-494-1465; Fax: 765-494-6790; E-mail: cushman@purdue.edu. Yves Pommier: Phone: 301-656-8086; Fax: 301-656-0752; E-mail: pommier@nh.gov.

‡Authors contributed equally to this work.

¹Purdue University.

²National Cancer Institute, Bethesda, MD

List of abbreviations: DMF, *N,N*-dimethylformamide; DMSO, dimethyl sulfoxide; DPC, DNA-protein crosslink; ICE, immunocomplex of enzyme; MGM, mean graph midpoint; NCI, National Cancer Institute; PI, propidium iodide; TFA, trifluoroacetic acid; Top1, topoisomerase I; Top1cc, topoisomeraseI–DNA cleavage complex; SAR, structure-activity relationship.




Figure 1. A. Mean centered graph generated for GI_{50} data across the NCI60. **B.** Negative logarithms of MGM for **11**, **14** and **20** are indicated under corresponding plots along with Pearson's correlations between the GI_{50} activity profiles with that of **20**.